



PerkinElmer Continues to Drive Reagent Expansion with Executive Appointment of Martina Bielefeld-Sevigny as Vice President, Drug Discovery and Research Reagents

WALTHAM, Mass., Nov 04, 2008 (BUSINESS WIRE) --PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced the appointment of Martina Bielefeld-Sevigny, Ph.D., as vice president and general manager, drug discovery and research reagents. In this role, she will be responsible for driving expansion of the reagents portfolio for its Bio-discovery business.

Bielefeld-Sevigny, who most recently served as director, Molecular Pharmacology, within PerkinElmer Bio-discovery's reagents business, and led the Company's Center of Excellence in Montreal, Canada, brings over 20 years of distinguished life sciences industry experience to her new position, with both a strong commercial and technical background.

"Martina is a proven scientific, operational and business leader and has demonstrated outstanding results in her R&D role in recent years," said Richard Eglon, Ph.D., president, Bio-discovery, PerkinElmer. "We are confident that her commitment to developing and leading high performance initiatives will help to grow PerkinElmer's role as an industry leader in providing integrated solutions to meet emerging customer needs."

"It has been a pleasure to be part of the exciting scientific and business innovations led by PerkinElmer's Bio-discovery business," said Bielefeld-Sevigny, "I look forward to continuing our successful efforts to expand our reagent offerings in drug discovery and academic research."

Prior to joining PerkinElmer in 2004, Bielefeld-Sevigny held the position of director, Process Development at DSM Biologics of Montreal. Before DSM Biologics, Bielefeld-Sevigny held a series of posts at Pharmacia Biotech, Inc., in Freiburg, Germany, Uppsala, Sweden, and Montreal, Canada, between 1990 and 1998, lastly serving as Scientific Affairs Manager.

Bielefeld-Sevigny received her Ph.D. from the Institute for Microbiology, DA 1/4sseldorf, Germany, and is the author of numerous scientific publications.

About PerkinElmer Bio-discovery

PerkinElmer's Bio-discovery business provides a comprehensive offering of enabling technologies and services including biochemistry, detection systems, cell imaging, and liquid handling to accelerate life sciences research, from drug discovery to academic research.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) markets into which we sell our products decline or do not grow as anticipated; (4) our failure to adequately protect our intellectual property; (5) the loss of any of our licenses or licensed rights; (6) our ability to compete effectively; (7)

fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) disruptions in the supply of raw materials and supplies; (9) our ability to produce an adequate quantity of products to meet our customers' demands; (10) the manufacture and sale of products may expose us to product liability claims; (11) our failure to maintain compliance with applicable government regulations; (12) regulatory changes; (13) our failure to comply with health care industry regulations; (14) economic, political and other risks associated with foreign operations; (15) our ability to retain key personnel; (16) restrictions in our credit agreements; (17) our ability to realize the full value of our intangible assets; and customers' demands; (10) the manufacture and sale of products may expose us to product liability claims; (11) our failure to maintain compliance with applicable government regulations; (12) regulatory changes; (13) our failure to comply with health care industry regulations; (14) economic, political and other risks associated with foreign operations; (15) our ability to retain key personnel; (16) restrictions in our credit agreements; (17) our ability to realize the full value of our intangible assets; and (18) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: PerkinElmer, Inc.

For further information regarding PerkinElmer:

Media:
PerkinElmer, Inc.
Mario R. Fante, 781-663-5602
mario.fante@perkinelmer.com

Copyright Business Wire 2008

News Provided by COMTEX